RVVTF
Revive Therapeutics Ltd.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
0.02
▼ 0.00 (14.29%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.02
Prev close
0.02
Day high
0.02
Day low
0.02
Volume
114.19K
Market cap
$7.84M
P/E (TTM)
—
52W range
0.00 – 0.06
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
6.59M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 10, 24 | Lindzon (Andrew Stuart) Director of Issuer |
BUY | 333.00K | $3.66K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Lindzon (Andrew Stuart) |
Director of Issuer | — | Acquisition or disposition in the public market |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-30.77%
-29.4%
1M
-10.00%
-13.7%
3M
-21.74%
-24.8%
6M
+100.00%
+88.9%
YTD
+125.00%
+112.7%
1Y
+28.57%
+8.6%
3Y
-30.77%
-104.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$7.84M
Enterprise value$7.94M
Revenue (TTM)—
Gross profit—
EBITDA$-1.30M
Net income$-10.62M
EPS (TTM)$-0.02
Free cash flow$240.13K
Total cash$12.66K
Total debt$70.77K
Book value / share$-0.01
Shares outstanding435.68M
Float429.35M
Short % of float—
Dividend yield—
Beta (5Y)-1.85
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-6.09
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-1108.41%
Return on assets-16.44%
Debt / equity—
Current ratio0.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $144.81K | $1.11M | $3.58M | $15.16M | -87.0% |
| Selling, general & admin | $1.40M | $2.06M | $1.77M | $2.49M | -31.9% |
| Total operating expense | $1.65M | $3.29M | $5.52M | $17.83M | -49.8% |
| Operating income | -$1.65M | -$3.29M | -$5.52M | -$17.83M | +49.8% |
| Net interest income | -$2.30K | $38.69K | $64.61K | $52.80K | -105.9% |
| Pre-tax income | -$11.01M | -$5.62M | -$6.32M | -$17.81M | -96.0% |
| Net income | -$11.01M | -$5.62M | -$6.32M | -$17.81M | -96.0% |
| Net income to common | -$11.01M | -$5.62M | -$6.32M | -$17.81M | -96.0% |
| Basic EPS | -0.03 | -0.01 | -0.02 | -0.06 | -200.0% |
| Diluted EPS | -0.03 | -0.01 | -0.02 | -0.06 | -200.0% |
| EBIT | -$11.01M | -$5.60M | -$6.28M | -$17.74M | -96.7% |
| EBITDA | -$11.01M | -$5.60M | -$6.28M | -$17.74M | -96.7% |
| Basic shares | 419.71M | 380.48M | 339.37M | 319.76M | +10.3% |
| Diluted shares | 419.71M | 380.48M | 339.37M | 319.76M | +10.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $14.56K | $773.07K | $2.09M | $3.92M | -98.1% |
| Cash & short-term investments | $14.56K | $773.07K | $2.09M | $3.92M | -98.1% |
| Total current assets | $68.41K | $1.14M | $2.35M | $4.16M | -94.0% |
| Property, plant & equipment | $828 | $1.08K | $1.40K | $1.84K | -23.0% |
| Goodwill & intangibles | $0 | $9.38M | $11.72M | $12.50M | -100.0% |
| Total assets | $205.02K | $10.64M | $14.25M | $17.07M | -98.1% |
| Total current liabilities | $3.51M | $3.32M | $3.44M | $4.17M | +5.7% |
| Long-term debt | $66.87K | — | $60.00K | $60.00K | — |
| Total debt | $66.87K | $25.22K | $219.69K | $327.73K | +165.2% |
| Total liabilities | $3.66M | $3.40M | $3.60M | $4.46M | +7.5% |
| Retained earnings | -$77.20M | -$66.19M | -$60.57M | -$54.25M | -16.6% |
| Shareholder equity | -$3.46M | $7.23M | $10.65M | $12.60M | -147.8% |
| Working capital | -$3.45M | -$2.18M | -$1.08M | -$2.21K | -57.8% |
| Net tangible assets | -$3.46M | -$2.15M | -$1.07M | $102.72K | -61.0% |
| Shares issued | 425.21M | 418.56M | 357.65M | 321.42M | +1.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.01M | -$5.62M | -$6.32M | -$17.81M | -96.0% |
| Depreciation & amortisation | $248 | $328 | $434 | $578 | -24.4% |
| Stock-based compensation | $124.14K | $136.45K | $0 | $1.04M | -9.0% |
| Change in working capital | $602.75K | -$185.54K | -$747.61K | $3.54M | +424.9% |
| Operating cash flow | -$767.66K | -$3.29M | -$6.03M | -$13.06M | +76.7% |
| Investing cash flow | -$30.00K | $0 | — | $0 | — |
| Financing cash flow | $39.15K | $1.98M | $4.20M | $376.35K | -98.0% |
| Free cash flow | -$767.66K | -$3.29M | -$6.03M | -$13.06M | +76.7% |
| End cash position | $14.56K | $773.07K | $2.09M | $3.92M | -98.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $0 | $0 | $0 | $0 | $0 | — | — |
| Selling, general & admin | $456.63K | $274.74K | $205.86K | $321.83K | $420.93K | — | +66.2% |
| Total operating expense | $461.63K | $280.48K | $218.11K | $334.81K | $480.59K | — | +64.6% |
| Operating income | -$461.63K | -$280.48K | -$218.11K | -$334.81K | -$480.59K | — | -64.6% |
| Net interest income | -$2.24K | -$2.82K | -$1.74K | -$1.58K | -$840 | — | +20.4% |
| Pre-tax income | -$506.50K | -$238.72K | -$281.75K | -$9.60M | -$577.18K | — | -112.2% |
| Net income | -$506.50K | -$238.72K | -$281.75K | -$9.60M | -$577.18K | — | -112.2% |
| Net income to common | -$506.50K | -$238.72K | -$281.75K | -$9.60M | -$577.18K | — | -112.2% |
| Basic EPS | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
| Diluted EPS | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
| EBIT | -$506.50K | -$238.72K | -$281.75K | -$9.60M | -$577.18K | — | -112.2% |
| EBITDA | -$506.46K | -$238.68K | -$281.70K | -$9.60M | -$577.12K | — | -112.2% |
| Basic shares | 435.68M | 435.68M | 429.30M | — | 418.56M | 418.56M | 0.0% |
| Diluted shares | 435.68M | 435.68M | 429.30M | — | 418.56M | 418.56M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.66K | $12.88K | $20.95K | $14.56K | $46.42K | — | -1.7% |
| Cash & short-term investments | $12.66K | $12.88K | $20.95K | $14.56K | $46.42K | — | -1.7% |
| Total current assets | $149.33K | $128.88K | $113.25K | $68.41K | $111.80K | — | +15.9% |
| Property, plant & equipment | $687 | $734 | $781 | $828 | $890 | — | -6.4% |
| Goodwill & intangibles | — | — | — | $0 | $9.38M | $9.38M | — |
| Total assets | $281.77K | $261.38K | $249.81K | $205.02K | $9.63M | — | +7.8% |
| Total current liabilities | $4.15M | $3.85M | $3.60M | $3.51M | $3.54M | — | +7.9% |
| Long-term debt | $70.77K | $69.49K | $68.18K | $66.87K | $65.57K | — | +1.8% |
| Total debt | $70.77K | $69.49K | $68.18K | $66.87K | $65.57K | — | +1.8% |
| Total liabilities | $4.31M | $4.00M | $3.75M | $3.66M | $3.69M | — | +7.6% |
| Retained earnings | -$78.22M | -$77.72M | -$77.48M | -$77.20M | -$67.60M | — | -0.7% |
| Shareholder equity | -$4.02M | -$3.74M | -$3.50M | -$3.46M | $5.94M | — | -7.6% |
| Working capital | -$4.01M | -$3.72M | -$3.49M | -$3.45M | -$3.43M | — | -7.6% |
| Net tangible assets | -$4.02M | -$3.74M | -$3.50M | -$3.46M | -$3.44M | — | -7.6% |
| Shares issued | 435.68M | 435.68M | 435.68M | 425.21M | 418.56M | — | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$506.50K | -$238.72K | -$281.75K | -$9.60M | -$577.18K | -112.2% |
| Depreciation & amortisation | $47 | $48 | $46 | $62 | $62 | -2.1% |
| Stock-based compensation | $221.77K | $0 | $19.95K | $0 | $124.14K | — |
| Change in working capital | $282.15K | $226.23K | $49.41K | $74.90K | $394.13K | +24.7% |
| Operating cash flow | -$218 | -$8.07K | -$142.41K | -$6.02K | -$73.99K | +97.3% |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $0 | $0 | $148.80K | -$25.85K | $65.00K | — |
| Free cash flow | -$218 | -$8.07K | -$142.41K | -$6.02K | -$73.99K | +97.3% |
| End cash position | $12.66K | $12.88K | $20.95K | $14.56K | $46.42K | -1.7% |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.51%
Held by institutions0.00%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.02
-15.09% from price
SMA 20
0.02
-10.00% from price
SMA 50
0.02
-11.68% from price
SMA 100
0.02
-22.11% from price
SMA 200
0.02
+0.06% from price
EMA 12
0.02
-12.63% from price
EMA 26
0.02
-12.37% from price
EMA 50
0.02
-13.87% from price
RSI (14)
43.4
Neutral
MACD (12,26,9)
0.00
Hist -0.00
ATR (14)
0.00
23.81% of price
Realised vol 30D
121.4%
Annualised
Bollinger upper
0.02
20, 2σ
Bollinger lower
0.02
20, 2σ
50 / 200 cross
Golden
0.02 vs 0.02
Trend bias
Above 200
+0.06%
Risk profile
Beta vs SPY
0.65
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
121.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-67.3%
Peak to trough
Max drawdown 5Y
-98.9%
Peak to trough
ATR 14
0.00
23.81% of price
Beta (reported)
-1.85
5Y monthly, from filing
Headlines
Revive Therapeutics Announces Proposed Shares for Debt Settlement
ACCESS Newswire · 3d ago
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
ACCESS Newswire · 3d ago
Revive Therapeutics Reports Grant of Options
ACCESS Newswire · 8d ago
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
ACCESS Newswire · 10d ago
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
ACCESS Newswire · 38d ago
Revive Therapeutics Announces Proposed Private Placement
ACCESS Newswire · 57d ago
Canadian Investment Regulatory Organization Trading Halt - RVV
CNW Group · 75d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.